Global Peptide Therapeutics Market & Clinical Pipeline Insight 2016

Publish Date:- Mar-2016       No Of Pages (1200)

Electronic Access - Single User License $2400 Buy Now
CD-ROM Mail Delivery $3300Buy Now
Hard Copy Mail Delivery $4200 Buy Now
Electronic Access - Multi-User License $4800 Buy Now


Investigators are looking for different molecular entities that could be used for the development of viable therapeutics with commercial potential. Peptide therapeutics are one such category that has gained significant attention in past years. Several products have been launched in global market for different indications. Significant investments have been made by pharmaceutical companies in research and development (R&D) segment in order to come forth with innovative products. They also serve as building blocks for other therapeutics due to which it has become essential to study their nature in depth. In this way, it could be expected that peptide therapeutics for different ailments would be commercialized in global market in coming years.

Pharmacological profiles of peptide therapeutics is quite good due to which their numbers are increasing in global market. Inherently, peptide therapeutic offers various benefits like higher safety and efficacy levels along with higher tolerability. Metabolism of peptide therapeutics is quite predictable and it can be changed by investigators. In this way, higher control over pharmacological parameters could be observed. They can also be developed synthetically due to which variability could be made during their development. In this way, they are highly malleable and could be changes according to the requirements of drug development program. Their rate of development is high and low attrition rates related to peptide therapeutics have been also observed.

Pipeline of peptide therapeutics is quite strong due to which new products are expected to enter in global market in coming years. Several peptide therapeutics have already entered in various phases of clinical trials. Development of positive results will accelerate their market introduction in coming years. They are peptide in nature due to which chances of degradation is high, poor chemical stability and absorbance are some common caveats with their development. Immunogenicity is another factor that affect the efficacy of peptide therapeutics as some patients may develop severe side effects. Investigators have developed various procedure by which they are able to increase potency of peptide products. In this way, it could be observed that investigators are actively engaged in the development of peptide therapeutics.

Rapid discovery of peptide therapeutics is expected to increase the number of products in global market. Investigators are developing methods to identify new lead molecules that will serve as a basis for the development of new molecule. They are also being administrated in combination with other drugs to achieve higher therapeutic benefits. Alternate Route of Administration (RoA) is also being discovered for peptide drugs so as to maintain their efficacy. They are expected to have competition with small molecule drugs and development of new technologies which can hamper their marketing potential. Higher prices are other major factors that affect the commercialization potential of peptide therapeutics in global market. These factors have to consider by pharmaceutical companies while formulating marketing strategies.

Peptide therapeutics are versatile in nature due to which they can be used for the treatment of various disorders. Cancer, Central Nervous System (CNS), cardiovascular diseases, respiratory diseases and metabolic disorders are some the major segments where presence of peptide therapeutics could be observed. Besides this, different types of insulin has been developed by engineering peptide molecules. Their pharmacological efficacy is expected to be improved with time and new molecules are expected to enter in global market. Pharmaceutical companies have to come forth with new molecules in order to increase market shares of peptide therapeutics. Strong clinical pipeline indicates that the pharmaceutical firms are actively engaged in the development of peptide therapeutics. In this way, it could be expected that market size of global peptide therapeutics market will increase in coming years.

 

Peptide Segment Included In Report:

Cyclic-Peptide, Polypeptide, Glycopeptide, Oligopeptide, Depsipeptide, Neuropeptide, Dipeptides, Natriuretic Peptide, Lipopeptide, Opioid Peptide, Peptide Vaccine, Antimicrobial Cationic Peptide & Insulin

 

“Global Peptide Therapeutics Market & Clinical Pipeline Insight 2016” Report Highlights:

  • Introduction to Peptides
  • Mechanism of Action: Peptide Therapeutics, Peptide Vaccine & Peptide Hormone
  • Global Peptide Therapeutics Market Dynamics
  • Global Peptide Clinical Pipeline by Company, Indication & Phase
  • Global Peptide Pipeline: 722 Peptides
  • Majority Peptides in Preclinical Phase: 308 Peptides
  • Commercially Available Peptides: 136 Peptides

 


Investigators are looking for different molecular entities that could be used for the development of viable therapeutics with commercial potential. Peptide therapeutics are one such category that has gained significant attention in past years. Several products have been launched in global market for different indications. Significant investments have been made by pharmaceutical companies in research and development (R&D) segment in order to come forth with innovative products. They also serve as building blocks for other therapeutics due to which it has become essential to study their nature in depth. In this way, it could be expected that peptide therapeutics for different ailments would be commercialized in global market in coming years.

Pharmacological profiles of peptide therapeutics is quite good due to which their numbers are increasing in global market. Inherently, peptide therapeutic offers various benefits like higher safety and efficacy levels along with higher tolerability. Metabolism of peptide therapeutics is quite predictable and it can be changed by investigators. In this way, higher control over pharmacological parameters could be observed. They can also be developed synthetically due to which variability could be made during their development. In this way, they are highly malleable and could be changes according to the requirements of drug development program. Their rate of development is high and low attrition rates related to peptide therapeutics have been also observed.

Pipeline of peptide therapeutics is quite strong due to which new products are expected to enter in global market in coming years. Several peptide therapeutics have already entered in various phases of clinical trials. Development of positive results will accelerate their market introduction in coming years. They are peptide in nature due to which chances of degradation is high, poor chemical stability and absorbance are some common caveats with their development. Immunogenicity is another factor that affect the efficacy of peptide therapeutics as some patients may develop severe side effects. Investigators have developed various procedure by which they are able to increase potency of peptide products. In this way, it could be observed that investigators are actively engaged in the development of peptide therapeutics.

Rapid discovery of peptide therapeutics is expected to increase the number of products in global market. Investigators are developing methods to identify new lead molecules that will serve as a basis for the development of new molecule. They are also being administrated in combination with other drugs to achieve higher therapeutic benefits. Alternate Route of Administration (RoA) is also being discovered for peptide drugs so as to maintain their efficacy. They are expected to have competition with small molecule drugs and development of new technologies which can hamper their marketing potential. Higher prices are other major factors that affect the commercialization potential of peptide therapeutics in global market. These factors have to consider by pharmaceutical companies while formulating marketing strategies.

Peptide therapeutics are versatile in nature due to which they can be used for the treatment of various disorders. Cancer, Central Nervous System (CNS), cardiovascular diseases, respiratory diseases and metabolic disorders are some the major segments where presence of peptide therapeutics could be observed. Besides this, different types of insulin has been developed by engineering peptide molecules. Their pharmacological efficacy is expected to be improved with time and new molecules are expected to enter in global market. Pharmaceutical companies have to come forth with new molecules in order to increase market shares of peptide therapeutics. Strong clinical pipeline indicates that the pharmaceutical firms are actively engaged in the development of peptide therapeutics. In this way, it could be expected that market size of global peptide therapeutics market will increase in coming years.

 

Peptide Segment Included In Report:

Cyclic-Peptide, Polypeptide, Glycopeptide, Oligopeptide, Depsipeptide, Neuropeptide, Dipeptides, Natriuretic Peptide, Lipopeptide, Opioid Peptide, Peptide Vaccine, Antimicrobial Cationic Peptide & Insulin

 

“Global Peptide Therapeutics Market & Clinical Pipeline Insight 2016” Report Highlights:

  • Introduction to Peptides
  • Mechanism of Action: Peptide Therapeutics, Peptide Vaccine & Peptide Hormone
  • Global Peptide Therapeutics Market Dynamics
  • Global Peptide Clinical Pipeline by Company, Indication & Phase
  • Global Peptide Pipeline: 722 Peptides
  • Majority Peptides in Preclinical Phase: 308 Peptides
  • Commercially Available Peptides: 136 Peptides

 

1. Introduction to Peptides

 

2. Mechanism of Action: Peptide Therapeutics, Peptide Vaccine & Peptide Hormone

  2.1 Peptide Therapeutics

  2.2 Peptide Vaccine

  2.3 Peptide Hormone

 

3. Global Peptide Therapeutics Market Overview

  3.1 Current Market Scenario

  3.2 Global eptide Pipeline Overview

 

4. Global Peptide Therapeutics Market Dynamics

  4.1 Market Growth Drivers

    4.1.1 Escalating Demand for Better Therapeutics

    4.1.2 Research & Development

    4.1.3 Advanced Peptide Synthesis Technology

    4.1.4 Multiple Disease Indications

    4.1.5 Strong Clinical Pipeline

  4.2 Peptide Therapeutics Commercialization Challenges

 

5. Global Peptide Therapeutics Market Future Prospects

 

6. Cyclic Peptides Cinical Insight by Company, Indication & Phase

  6.1 Preclinical till Preregistration

 

7. Dipeptides Cinical Insight by Company, Indication & Phase

  7.1 Preclinical till Preregistration

 

8. Depsipeptides Cinical Insight by Company, Indication & Phase

  8.1 Research till Phase-III

 

 

9. Glycopeptide Cinical Insight by Company, Indication & Phase

  9.1 Preclinical till Phase-II

 

10. Insulin Cinical Insight by Company, Indication & Phase

  10.1 Preclinical till Registered

 

11. Lipopeptides Cinical Insight by Company, Indication & Phase

  11.1 Research till Phase-III

 

12. Natriuretic Peptide Cinical Insight by Company, Indication & Phase

  12.1 Preclinical till Phase-III

 

13. Neuropeptide Cinical Insight by Company, Indication & Phase

  13.1 Preclinical till Phase-II

 

14. Oligopeptides Cinical Insight by Company, Indication & Phase

  14.1 Research till Preregistration

 

15. Opioid-Peptide Cinical Insight by Company, Indication & Phase

  15.1 Preclinical till Preregistration

 

16. Peptides Cinical Insight by Company, Indication & Phase

  16.1 Research till Registered

 

17. Multiple Peptides Cinical Insight by Company, Indication & Phase

  17.1 Research till Preregistration

 

18. Marketed Peptides Cinical Insight by Company, Indication & Phase

  18.1 Cyclic Peptides

  18.2 Dipeptides

  18.3 Depsipeptides

  18.4 Glycopeptides

  18.5 Insulins

  18.6 Natriuretic-Peptides

  18.7 Neuropeptides

  18.8 Oligopeptides

  18.9 Opioid-Peptides

  18.10 Peptides

  18.11 Multiple Peptides

 

19. Competitive Landscape

  19.1 Amgen

  19.2 Amylin Pharmaceuticals

  19.3 Apitope Technology

  19.4 BioPartners

  19.5 BiondVax Pharmaceuticals Ltd

  19.6 Boehringer Ingelheim

  19.7 Circassia

  19.8 Corden Pharma (Peptisyntha)

  19.9 Eli Lily

  19.10 Galena Biopharmaceuticals

  19.11 GlaxoSmithKline

  19.12 Hyperion Therapeutics

  19.13 ImmunoCellular Therapeutics

  19.14 Ipsen

  19.15 Lonza

  19.16 Merck

  19.17 NovoNordisk

  19.18 Par Pharmaceuticals

  19.19 PeptiDream

  19.20 Roche

  19.21 Sanofi

  19.22 Tarix Pharmaceuticals

 

 


Figure 1-1: Components of Peptide

Figure 1-2: Features of Peptide Therapeutics

Figure 2-1: Benefits of Peptide Modifications

Figure 2-2: Benefits of Computational Methods

Figure 2-3: Different Types of Peptide Formulation Vehicles

Figure 2-4: Mechanism of Vibativ

Figure 2-5: Mechanism of Liraglutide

Figure 2-6: Mechanism of Goserelin

Figure 2-7: Formulation of Orally Administrated Peptide Therapeutics

Figure 2-8: Mechanism of Peptide Vaccines

Figure 2-9: Mechanism of Live Vaccines

Figure 2-10: Mechanism of Toxoid & Inactivated Vaccine

Figure 2-11: Mode of Action of Peptide Cancer Vaccines

Figure 2-12: Mechanism of Peptide Hormones

Figure 2-13: Mechanism of Insulin

Figure 2-14: Mechanism of Genotropin

Figure 2-15: Mechanism of Pitressin

Figure 2-16: Mechanism of Glucagon

Figure 3-1: Global Peptide Market (US$ Billion), 2014-2020

Figure 3-2: Peptide Pipeline by Phase (%), 2016

Figure 3-3: Peptide Pipeline by Phase (Numbers), 2016

Figure 3-4: Cyclic Peptides Pipeline by Phase (%), 2016

Figure 3-5: Cyclic Peptides Pipeline by Phase (Numbers), 2016

Figure 3-6: Dipeptides Pipeline by Phase (%), 2016

Figure 3-7: Dipeptides Pipeline by Phase (Numbers), 2016

Figure 3-8: Depsipeptides Pipeline by Phase (%), 2016

Figure 3-9: Depsipeptides Pipeline by Phase (Numbers), 2016

Figure 3-10: Glycopeptides Pipeline by Phase (%), 2016

Figure 3-11: Glycopeptides Pipeline by Phase (Numbers), 2016

Figure 3-12: Insulin Pipeline by Phase (%), 2016

Figure 3-13: Insulin Pipeline by Phase (Numbers), 2016

Figure 3-14: Lipopeptides Pipeline by Phase (%), 2016

Figure 3-15: Lipopeptides Pipeline by Phase (Numbers), 2016

Figure 3-16: Natriuretic Peptides Pipeline by Phase (%), 2016

Figure 3-17: Natriuretic Peptides Pipeline by Phase (Numbers), 2016

Figure 3-18: Neuropeptides Pipeline by Phase (%), 2016

Figure 3-19: Neuropeptides Pipeline by Phase (Numbers), 2016

Figure 3-20: Oligopeptides Pipeline by Phase (%), 2016

Figure 3-21: Oligopeptides Pipeline by Phase (Numbers), 2016

Figure 3-22: Opioid-Peptides Pipeline by Phase (%), 2016

Figure 3-23: Opioid-Peptides Pipeline by Phase (Numbers), 2016

Figure 3-24: Multiple Peptides Pipeline by Phase (%), 2016

Figure 3-25: Multiple Peptides Pipeline by Phase (Numbers), 2016

Figure 4-1: Global Peptide Therapeutics Market Growth Drivers

Figure 4-2: Global Peptide Therapeutics Market Commercialization Challenges